BERKELEY, CA (UroToday.com) - Our tertiary urogynaecology unit has undertaken a high volume of intradetrusor Botox for detrusor overactivity (DO) refractory to medical treatment for over 3 years. Prior to the introduction of Mirabegron, our patients had a choice only between intradetrusor Botox and sacral neuromodulation (SNM).
SNM traditionally has been provided by the urology team. Patients choosing SNM have had to go through the referral process to urolog and reassessment (history/physical examination and potentially video urodynamics). This meant increased waiting times.
Financial limitations meant that if patients were not eligible for SNM funding, they would then need to await theatre slots/outpatient availability for Botox. Botox, on the other hand, has been well known due to the high volumes undertaken by our unit. The waiting list being shorter and the same urogynaecology team in charge meant continuity of care with quicker access and results.
A study exploring a woman's underlying reasons for choice between the 2 treatment modalities has not been previously undertaken. Our setting seemed the ideal opportunity to conduct this project with an aim to enhance the positive experiences and eliminate the negatives.
It was a clinical revelation.
Written by:
Pooja Balchandra as part of Beyond the Abstract on UroToday.com. This initiative offers a method of publishing for the professional urology community. Authors are given an opportunity to expand on the circumstances, limitations etc... of their research by referencing the published abstract.
Department of Urogynaecology, St James's University Hospital, Leeds UK
More Information about Beyond the Abstract